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Abstract
Currently, MVA virus vectors carrying HIV-1 genes are being developed as HIV-1/AIDS prophylactic/therapeutic vaccines.
Nevertheless, little is known about the impact of these vectors on human dendritic cells (DC) and their capacity to present
HIV-1 antigens to human HIV-specific T cells. This study aimed to characterize the interaction of MVA and MVA expressing
the HIV-1 genes Env-Gag-Pol-Nef of clade B (referred to as MVA-B) in human monocyte-derived dendritic cells (MDDC) and
the subsequent processes of HIV-1 antigen presentation and activation of memory HIV-1-specific T lymphocytes. For these
purposes, we performed ex vivo assays with MDDC and autologous lymphocytes from asymptomatic HIV-infected patients.
Infection of MDDC with MVA-B or MVA, at the optimal dose of 0.3 PFU/MDDC, induced by itself a moderate degree of
maturation of MDDC, involving secretion of cytokines and chemokines (IL1-ra, IL-7, TNF-a, IL-6, IL-12, IL-15, IL-8, MCP-1, MIP-
1a, MIP-1b, RANTES, IP-10, MIG, and IFN-a). MDDC infected with MVA or MVA-B and following a period of 48 h or 72 h of
maturation were able to migrate toward CCL19 or CCL21 chemokine gradients. MVA-B infection induced apoptosis of the
infected cells and the resulting apoptotic bodies were engulfed by the uninfected MDDC, which cross-presented HIV-1
antigens to autologous CD8+ T lymphocytes. MVA-B-infected MDDC co-cultured with autologous T lymphocytes induced a
highly functional HIV-specific CD8+ T cell response including proliferation, secretion of IFN-c, IL-2, TNF-a, MIP-1b, MIP-1a,
RANTES and IL-6, and strong cytotoxic activity against autologous HIV-1-infected CD4+ T lymphocytes. These results
evidence the adjuvant role of the vector itself (MVA) and support the clinical development of prophylactic and therapeutic
anti-HIV vaccines based on MVA-B.
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Introduction
Since its sudden emergence in 1981, the HIV/AIDS infection,
which spread rapidly worldwide, has resulted in more than 60
million of infected people and more than 25 million deaths, and
remains a priority in the global public health as it continues to
expand. Indeed, currently there are more than 33 million of
infected individuals, with an incidence per year of around 3
million of newly infected persons and 2 million deaths (www.
unaids.org). Although since 1996 very effective antiretroviral
medications have been developed, which allow the control, in
most patients, of HIV-1 replication [1], this therapy is not a cure
as it fails to eradicate the virus and must be maintained for life,
involving the risks of the appearance of drug resistances and
adverse effects. In addition, given the high economic cost of this
therapy and the high degree of sanitary requirements that involves,
it is not universally accessible in resource-limited areas of the world,
where most of infected persons live. Therefore, the development of a
safe and effective preventive HIV-1 vaccine is a global public-health
priority to try to halt the HIV-1 pandemic [2–5].
Initial efforts in the development of an HIV-1 vaccine were
aimed at generating neutralizing antibodies (nAb) against the
envelope (Env) protein using recombinant gp120. Two of these
Env-based vaccines formulated in conventional adjuvant (alum)
were tested in phase III clinical trials without any protective effect
[6,7]. The great difficulty in inducing nAb and the growing body
of evidence demonstrating the important role of cytotoxic T
lymphocytes (CTL) to control HIV-1 infection prompted the
interest to develop T cell-based vaccines [2,3,5,8,9]. These T-cell
vaccines have been developed using HIV-1 plasmid DNA and
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HIV-1 genes inserted in viral vectors, mainly adenovirus vectors
and poxvirus vectors. From studies in non human primates (NHP),
T-cell vaccines are unlikely to impede the infection but rather can
help to control HIV-1 replication after infection, reducing the rate
of disease progression. A notable number of these type of vaccines
have been clinically tested but only four of them have reached
efficacy trials (phases III or IIb). The results of two of these efficacy
trials (STEP and Phambili trials) employing adenovirus serotype 5
(Ad5)-based vaccine with inserted gag-pol-nef genes of HIV-1
clade B, were deeply disappointing, as the vaccination not only
failed to reduce the viral load after HIV-1 infection, but the
incidence of HIV-1 infection in the STEP trial was higher among
vaccinated individuals than in placebo-treated subjects [10–12].
Nevertheless, promising results were obtained in the more recent
efficacy trial with 16,402 volunteers in Thailand, using a prime-
boosting vaccination with a canarypox virus vectoring Env-Gag-
Pol HIV-1 genes (ALVAC-HIV) and a trimeric recombinant
gp120 (AIDSVAX B/E).Compared with placebo, 31% of
vaccinees were protected against HIV-1 infection [13]. Although
very modest, this rate of efficacy is relevant because is the first
description indicating that a protective immunization against
HIV-1 might be feasible. This study also underscores the relevance
of characterizing other poxvirus, such as MVA, as vaccine
candidates [14–16].
As anti-HIV vaccine candidates, attenuated poxvirus vectors
have a number of desirable features, including promising safety
profiles, the ability to incorporate substantial genetic material for
the expression of foreign gene products and the capacity to
efficiently activate the host immune responses to virally expressed
antigens [16–19].
Among poxviruses, MVA vectors (the attenuated poxvirus strain
modified vaccinia virus Ankara) have already generated very
promising results in in vitro studies [17,20] and in simian model of
HIV infection [21,22] and, on this basis, they are also currently
undergoing evaluation in human trials [23–26]. MVA expressing
Env-Gag-Pol-Nef HIV genes of clade B (MVA-B) has been
developed to pharmaceutical GMP degree and it is currently being
tested as either preventive vaccination in clinical trials in Spain
and it is expected to be tested as therapeutic vaccine in the near
future.
Moreover, previous non clinical studies have evaluated the
interaction of these vectors (MVA and MVA expressing HIV
genes) with myeloid derived dendritic cells (MDDC) using both ex
vivo [17,18,20,27] and animal models [28], showing that
combination of MDDC with these MVA vectors are able to
enhance cellular responses against HIV [17,20].
It is known the ability of dendritic cells (DC) to induce strong
cell-mediated immune responses by promoting the effector
functions of T helper (Th)-1 cells, cytotoxic T lymphocytes
(CTL) and natural killer (NK) cells, positioning them at the fore-
front of therapeutic applications in HIV infection [29–31] and also
in cancer treatment [32,33]. Results of studies in mouse models
suggest that immunization with DC loaded with HIV-1 viral
lysates, envelope glycoproteins or inactivated virus mount a potent
immune response against HIV [29,34,35]. In this context, the
objective of the present study was to study the interaction of MVA-
B with MDDC and the capacity of these cells to process and
present the HIV-1 antigens to autologous human T cells from
HIV-1-infected patients, in a 6–7 day co-culture system. To know
how MVA and MVA-B interact with MDDC is of paramount
importance for an adequate design of an efficient anti-HIV
vaccine based on MVA-B to be tested at both non clinical and
clinical studies. Results of the present study have demonstrated
that interaction of MVA-B with MDDC from HIV-infected
patients induces a strong HIV-specific CD8+ T cell response, thus
supporting the clinical development of a prophylactic and
therapeutic anti-HIV vaccine based on MVA-B.
Materials and Methods
Ethics Statement
This study received the approval of the Committee of Ethics
and Clinical Investigation of the Hospital Clı´nic Universitari
(Barcelona, Spain). All the subjects participating in the study were
recruited at the Service of Infectious Diseases & AIDS Unit of this
Hospital and gave their informed written consent.
Study individuals
Samples of EDTA-anticoagulated venous blood samples were
obtained from asymptomatic HIV-1-infected patients with base-
line CD4+ T cell counts .450 cells/mm3, and plasma viral load
(pVL) ,10,000 HIV-1 RNA copies/ml.
Generation of MDDC
Peripheral blood mononuclear cells (PBMC) were isolated
immediately after venous extraction by using a standard Ficoll
gradient. Cells were processed immediately after isolation. To
obtain human monocytes, PBMC were incubated in plastic plates
(2 h at 37uC) in a humidified atmosphere with 5% CO2 in MDDC
medium (serum-free XVIVO-15 medium, Lonza, Maryland,
USA) supplemented with 1% autologous serum, gentamicin (B/
Braun Medical, Melsungen, Germany) and fungizone (amphoter-
icin B, Bristol-MyersSquibb, Rueil-Malmaison, France) and 1 mM
zidovudine (Retrovir from GlaxoSmithKline, Madrid, Spain) to
avoid HIV infection. To obtain immature MDDC, adherent cells
were washed four times with pre-warmed MDDC medium and
then cultured for 5 days in the presence of 1000 U/ml each of
recombinant human IL-4 (Strathmann Biotec AG, Hamburg,
Germany) and recombinant human GM-CSF (Peprotech, Lon-
don, UK) on days 0 and 2. The purity and immunophenotype
were assessed by flow cytometry (see below).
Virus
The poxvirus strains used in this work included modified
vaccinia virus Ankara (MVA) obtained after 586 passages in CEF
cells (derived from clone F6 at passage 585) and the recombinant
MVA expressing the HIVBX08 gp120 and HIVIIIB Gag-Pol-Nef
genes from clade B (MVA-B). This nucleotide polygene construct
encodes a scrambled Nef variant lacking biological activity
[28,36]. Viruses were grown in primary CEF cells, purified
through two sucrose cushions and titrated by immunostaining
using rabbit polyclonal anti-vaccinia virus serum as previously
described [37].
MDDC infection with MVA and MVA-B viruses and MDDC
maturation
Immature MDDC in MDDC medium were exposed to MVA
and MVA-B vectors at a multiplicity of infection (MOI) of 0.003 to
10 PFU/MDDC. One hour later, fresh MDDC medium, IL-4 and
GM-CSF (1000 U/ml each) were added. To obtain mature
MDDC, a cocktail of recombinant human cytokines containing
TNF-a, IL-6 (1000 IU/ml each, Strathmann Biotec AG), IL-1b
(300 UI/ml, Strathmann Biotec AG) and PGE2 (1 mg/ml, Pfizer,
Madrid, Spain) was added at 2 h post-infection, and the mixture
was incubated for a whole period of 48 h. In parallel, for some
experiments, MDDC were pulsed with recombinant soluble p24
(Protein Sciences, Meriden, CT) at 1 mg/ml. Samples from each
HIV-1-Specific CD8+ Responses to MVA-B-Exposed DC
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experiment were set aside to evaluate intracellular expression of
Gag protein, viral protein expression using polyclonal antibodies
against the WR strain of vaccinia virus, the expression of the cell-
surface markers (at 16 h post-infection) and cytokine secretion (at
16 h and 48 h post-infection). The purity and immunophenotype
of mature MDDC were assessed by flow cytometry analysis using
commercially labeled monoclonal antibodies (mAbs) against
surface markers (see below, ‘‘flow cytometry’’).
Viability evaluation of MVA- or MVA-B-infected MDDC
The dual staining method with annexin V and 7-amino-
actinomycin (7AAD) was used, which allows to separate live cells
as negative for both dyes, dead cells as positive for 7AAD or for
both markers and apoptotic cells as positive for annexin V but
negative for 7AAD. Approximately 26105 pooled cells in 100 ml of
MDDC medium were added to individual wells in a round-
bottomed microtiter plate. Cells were washed with FACS buffer
and resuspended in 100 ml of annexin V binding buffer and then
FITC-annexin V was added (5 mg) to each well according to the
manufacturer’s protocol (ApoDETECT FITC-Annexin V Kit;
Zymed Laboratories, San Francisco, CA, USA). After 15 min of
incubation, 1 mg of 7AAD (Molecular Probes, Eugene, OR, USA)
was added to each well and the cells were incubated for 15 min
before flow cytometry analysis in a FACSalibur flow cytometer
ABC (BD Biosciences, San Diego, CA, USA). These experiments
were done in triplicates.
Flow cytometry
The immunophenotype of immature and mature MDDC was
assessed by two-colour flow cytometry using FITC- and PE-
conjugated mAbs against CD14, CD25, CD80, CD83, CD86,
CD11c, CD40 and HLA-DR and HLA-ABC (BD Biosciences).
Also, CD3, CD19 and CD56 were used to assess the purity of the
cell cultures, resulting to be lower than 2% of the total population.
FITC- and PE-conjugated isotype-matched monoclonal antibodies
of irrelevant specificity were used as negative controls. Intracellular
staining of Gag protein was performed as described elsewhere
[38,39] with minor modifications. Briefly, after staining MDDC
populations for cell-surface PE-CD86, cell were fixed and
permeabilized with BD Cytofix/Cytoperm kit (BD Biosciences)
and then incubated with anti-HIV Gag antibody conjugated to
fluorescein isothiacyanate (clone KC57; Beckman Coulter, Full-
erton, CA, USA) in Perm/Wash buffer. The cells were analyzed in
a FACScan flow cytometer (BD Biosciences). Data obtained were
analyzed with the FlowJo software (Tree Star, Inc. Ashland, OR,
USA). Expression of surface and intracellular markers was
measured by the percentage of positive cells and the geometric
mean fluorescence intensity. Cell populations were selected by
forward and side light-scatter parameters.
Fluorescence microscopy
Intracellular staining of Gag protein was performed as described
above. Intracellular staining of WR protein was performed as
described before with minor modifications [18]. Briefly, MDDC
populations were washed with PBS, fixed with 4% paraformalde-
hyde and permeabilized with BD Cytofix/Cytoperm kit. Cells
were incubated with primary anti-WR (anti-VV, obtained from R.
Blasco, INIA, Spain) antibodies, followed by FITC secondary
antibodies (BD Biosciences). Phagocytosis was further confirmed
by fluorescence microscopy. After the co-culture of uninfected
MDDC with CFSE-labelled MVA-B-infected MDDC (see below)
during 48 h with maturation cocktail, the cells were washed with
PBS and stained with PE-anti-CD80 antibody (BD Biosciences) at
4uC. In all the experiments, nucleus was stained for 10 minutes
using Hoechst staining and the cells were adhered on a slide with
Poly-L-Lysine (SIGMA- Aldrich, Madrid, Spain) for 30 minutes.
After that, the cells were observed under Nikon Eclipse E600
fluorescence microscope for green, red and blue fluorescence.
Cytokine and chemokine secretion by MDDC infected
with MVA and MVA-B
The secretion of cytokines by MDDC infected with MVA or
MVA-B was measured in the culture supernatant using the
Luminex technology (Cytokine Human 25-Plex Planel, Invitrogen,
Carlsbad, CA, USA), following the manufacturer’s instructions.
The following 25 mediators were tested: Eotaxin, GM-CSF, IL-
1b, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-
12p40/p70, IL-13, IL-15, IL-17, IFN-a, IFN-c, IP-10, MCP-1,
MIG, MIP-1a, MIP-1b, RANTES and TNF-a.
Activation of HIV-1-specific T lymphocytes by autologous
MDDC infected with MVA-B
As a source of enriched T cells we employed fresh PBMC
depleted of monocytes after adherence to plastic as indicated
above for the generation of MDDC. These monocyte-depleted
lymphocytes were washed (36) and resuspended in serum-free
XVIVO-10 medium and labeled with CFSE following the
instructions of the manufacturer (CellTrace CFSE cell prolifera-
tion kit, Molecular Probes, Paisley, UK). Autologous infected and
matured MDDC (66104 MDDC/well) were washed (46) and
resuspended in XVIVO-10 and co-cultured with autologous fresh
CFSE-labeled lymphocytes (26105 T-lymphocytes/well) in a final
volume of 0.2 ml in XVIVO-10 medium supplemented with
1 mM zidovudine to impede possible replication of endogenous
HIV-1. Infection with MVA or MVA-B and pulsing with soluble
recombinant HIV-1 p24, and maturation of MDDC were
performed as indicated above. The contribution of MDDC alone
and monocyte depleted PBMC (lymphocytes) alone was deter-
mined as negative controls of proliferation and cytokine secretion.
The co-cultures were done in triplicates at 37uC in a humidified
atmosphere of air with 5% CO2. After 6–7 days, proliferating
CD4+ (CD3+CD82) and CD8+ (CD3+CD8+) T cells were
determined by direct staining with mAbs conjugated with a-
CD3-Per-CP and a-CD8-PE. Mouse Ig isotypes mAbs (from BD
Biosciences) of unknown antigen specificity conjugated with PerCP
or PE were used as negative control mAbs. The stained cells were
analyzed on a FACSCalibur flow cytometer (BD Biosciences). T
cell populations were selected by forward and side light-scatter
parameters and sub-gated for CD4 or CD8 expression. Cells that
proliferated after the co-culture had lower intensity of CFSE
(CFSElow) in comparison with basal conditions. MVA, MVA-B or
p24 specific proliferation was expressed as the percentage of
CFSElow cells after co-culture with MDDC infected with MVA or
MVA-B or pulsed with soluble p24 minus the percentage of
(mock-treated) uninfected CFSElow cells. Aside from the CFSE-
proliferation of CD4+ and CD8+ T cells, the levels of IFN-c, IL-2,
IL-6 and TNF-a secreted in the co-culture supernatants were also
quantified at days 2 and 6 using the CBA assay (BD Bioscience)
and MIP-1a, MIP-1b, and RANTES were quantified using the
Luminex technology (see above).
Cytotoxicity assay
Effector cells were autologous monocyte-depleted PBMC
(lymphocytes) co-cultured for 6 days with MDDC mock-treated
or infected with MVA or MVA-B (MDDC:lymphocytes ratio of
1:10). After this co-culture period, CFSE staining of effector cells
was performed one day before the cytotoxicity assay. Target cells
HIV-1-Specific CD8+ Responses to MVA-B-Exposed DC
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were autologous CD8 and monocyte-depleted PBMC; depletion of
CD8+ cells (98%) was done with CD8-coupled MACS microbead
columns and MACS cell separator (Miltenyi Biotec, Inc). CD8-
depleted T cells (70% CD4+ T cells) were activated with PHA in
the presence of IL-2 (Proleukin, Chiron Corp, California, USA)
for 72 h before infection with a clade B X4R5 tropic HIV-1 virus
isolated from an HIV-infected patient (.200 pg of HIV-p24 at a
MOI of 0.1). After two days of infection, and also one day before
the cytotoxicity assay, determination of intracellular Gag expres-
sion by flow cytometry was performed in target cells to confirm
fully HIV infection (93.17% of Gag-positive cells was and 42,26%
of viable cells). Target cells were washed and seeded at 56103
cells/well at an effector/target ratio of 10:1 for 4 hours in
triplicates and then cells were collected and stained with anti-CD3-
PerCP and anti-CD8-PE and Annexin V-FITC. Cells were
resuspended in a final volume of 120 ml and were acquired during
60 seconds (at 1 ml/second). The cells were analyzed and counted
by Flow cytometry. Number of live target cells was assessed based
on SSC and FSC parameters (gate of live activated lymphocytes),
and CFSE, Annexin V, CD3 and CD8 labelling. Live CD4+ cell
count corresponded to the phenotype: CFSE-negative, CD3-
positive and CD8-negative, Annexin V-negative.
MDDC migration to a chemokine gradient of CCL19 or
CCL21
The migration of MDDC toward CCL19 or CCL21 chemo-
kines (from PeproTech, London, UK) was measured in a 96- plate
transwell chemotaxis chambers (Corning Costar, Cambridge, MA,
USA), using a polycarbonate filter of 5 mm pore size. Briefly,
150 ml of recombinant human CCL19 (300 ng/ml) or recombi-
nant human CCL21 (250 ng/ml) or medium alone were placed in
the lower wells. Upper wells were loaded with 50 ml of infected
MDDC cell suspensions (infected with MVA and MVA-B at 0.3
PFU/MDDC or mock infected) and maturated as above described
during 48 h and 72 h at a concentration of 106 MDDC/ml in
serum-free XVIVO-15 medium. Each condition was set up in
triplicates. The complete chamber was kept in a humidified
atmosphere with 5% CO2 at 37uC for 3 h. Thereafter, cell
suspensions in the upper well were removed and cells that had
migrated through the filter to the lower wells were counted by flow
cytometry for 1 minute. Values were given as percentage of
migrated cells 6 SEM in relation to the initial added cells.
Subsequently, migrated MDDC were collected and co-cultured
with CFSE labeled autologous lymphocytes at a 1:40 ratio (56103
MDDC: 26105 lymphocytes/well) in triplicates. Six days later,
proliferation was tested by flow cytometry using the CFSE assay as
described above.
Phagocytosis assay
The phagocytosis assay was performed as reported elsewhere
with minor modifications [40]. Immature MDDC were labeled
with CFSE following the manufacturer’s instructions and infected
with MVA-B at a MOI of 10 PFU/MDDC for 1 h (infected DC,
CFSE+). They were then extensively washed and mixed with non-
labeled and uninfected immature MDDC at a 2:1 ratio. One hour
later, fresh MDDC medium containing IL-4 and GM-CSF was
added. At 2 h post-infection, the maturation cocktail was added
and the mixture was incubated for a whole period of 48 h. As
negative controls, uninfected cells and infected cells were
separately cultured at the same conditions. Wells containing cell
mixtures and control cells were then washed several times with
cold PBS to aspirate noningested MDDC microvesicles. All the
cells were labeled with a PE-conjugated anti-CD80 mAb and
analyzed by FACS. CD80-PE labeled exclusively uninfected
MDDC because MVA-B-infected MDDC die following 48 post-
infection and do not undergo sufficient maturation to achieve the
expression of this marker as they die (see results). MDDC that
ingested apoptotic bodies derived from MVA-infected MDDC
were identified by their positive signal for both CFSE and CD80-
PE. Phagocytosis was further confirmed by fluorescence micros-
copy.
Analysis of HIV antigen cross-presentation by MVA-B-
infected MDDC
To assess whether the mechanism of HIV-1 antigen presenta-
tion by MVA-B-infected MDDC to autologous CD8+ T cells was
cross-presentation the following procedures were done. On day 2,
the initial MDDC culture (at a dose of 66104 cells/well) was
divided in two different cultures. On the one hand, one third of the
initial cell load (26104 cells/well) was exposed to MVA-B at the
highest tested concentration of 10 PFU/MDDC. One hour later,
cells were extensively washed, fresh MDDC medium containing
IL-4 and GM-CSF was added and the cells were incubated for
72 h (total culture time: 5 days). On the other hand, two thirds of
the initial culture (46104 cells/well) were incubated for 3
additional days in MDDC medium containing IL-4 and GM-
CSF (total culture time: 5 days) (uninfected immature MDDC). At
this time, the whole content of infected MDDC, consisting of a
mixture of apoptotic cells and apoptotic bodies, was incubated for
two hours with the other two thirds of the initial culture
(uninfected immature MDDC), and then the maturation cocktail
containing TNF-a, IL-1b, IL-6 and PGE2 was added and the
mixture was incubated for 48 h. Afterwards, this mixture of
MDDC were co-cultured for 6–7 days with autologous T
lymphocytes to assess T cell proliferation as above indicated. In
some experiments, to further exclude a direct antigen presentation
mechanism by infected MDDC, the one third of MVA-B-infected
MDDC were heat-inactivated for 1 hour at 55uC.
Statistical analysis
Data were analyzed using the GraphPad Prism software
(GraphPad Software, San Diego, CA, USA). Comparisons among
groups were performed by unpaired and paired Student’s t-test.
For the analysis of correlation the non-parametric test of
Spearman was applied. For all tests used, two sided p values less
than 0.05 were considered to indicate statistical significance.
Correlation coefficients (r2) were used to evaluate the goodness of
fit of linear and curve models.
Results
Upon MVA-B infection, MDDC expressed intracellular
Gag protein in a dose-dependent manner
MDDC were generated from samples of chronically HIV-1-
infected patients with baseline CD4+ T lymphocytes above 450
cells/mm3, and pVL below 10,000 HIV-1 RNA copies/ml.
After MDDC generation, a flow cytometry analysis showed a
purity $95% and the phenotype observed was characteristic of
immature MDDC: mostly negative (.95%) for CD14, 100%
strongly positive for HLA-DR, mostly positive for CD40, CD11c,
CD209 (DC-SIGN) and CD86, and negative for CD80 and CD83
(data not shown). These immature MDDC were used for infection
with MVA and MVA-B. Using immunofluorescence microscopy
with anti-vaccinia virus antiserum (a-WR), we first confirmed that
at 16 h post-infection at 10 PFU/MDDC there was expression of
vaccinia virus proteins in the cytoplasm of MDDC infected with
either MVA-B (Figure 1A) or parental MVA (data not shown).
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Since MDDC support infection and expression of MVA genes
but do not support production of mature virus [17,20,41], a dose-
response study was performed to find the optimal infective dose for
a maximal intracellular expression of HIV-1 genes and a maximal
MDDC viability. To assess MVA-B infection in MDDC, flow
cytometry analysis of intracellular Gag protein and cell-surface
CD86 as a MDDC marker was performed 16 h post-infection at a
dose range of 0.003–3.3 or at a single dose of 10 PFU/MDDC
(Figure 1B–D). As a negative control of HIV-1 genes expression,
MDDC infected with the parental strain MVA were used. As
shown in Figure 1B–C, intracellular Gag expression in MDDC
(CD86+) showed a linear positive response over a viral dose from
0.003 to 0.33 (slope: 96.823, r2 = 0.9996), while at higher viral
doses, non-linear increases were found (65.3% and 75.4% at 1 and
3.3 viral dose, respectively).
Using immunofluorescence microscopy, intracellular Gag was
observed along the cytoplasm of MDDC infected with MVA-B (at
a 10 PFU/MDDC dose), while no Gag was detected in MDDC
infected with the parental MVA (Figure 1D). Of note, and in
agreement with our previous studies of MDDC infected with
MVA [18], we observed an apoptotic nucleus morphology in the
infected cells at 16 h post-infection with the highest viral doses (10
PFU/MDDC) (Figure 1A and D).
Effects of MVA and MVA-B infection on the viability and
maturation of MDDC
In previous studies, we [27] and other researchers [17,20] had
shown that MVA infection of immature human MDDC caused
extensive cytopathic effects, particularly at late times post-infection
and at high viral doses, that lead to rRNA breakdown and
apoptosis [18]. Thus, we next sought to precisely characterize the
effects on the MDDC viability following MVA-B infection. First, a
time-course measurement of cell viability was performed by flow
cytometry defining viable cells as negative for both Annexin V-
FITC and 7AAD. As shown in Figure 2A, the viability of MDDC
infected with MVA-B at a MOI of 10 PFU/MDDC decreased as a
function of time, being virtually null at 72 h post-infection, 5% at
48 h post-infection and 10% at 24 h post-infection. The viability
decay analysis with doses of MVA-B of 1 and 3.3 PFU/MDDC
gave similar results to those shown in Figure 2A (data not shown).
Figure 1. MDDC infected with MVA-B expressed intracellular Gag protein in a dose-dependent manner. MDDC were infected with serial
three-fold dilutions of a stock of MVA-B, from 0.003 to 10 PFU/MDDC. After MVA-B infection of MDDC, Gag and CD86 expression was measured by
flow cytometry. (A) Intracellular viral protein expression in MDDC observed by fluorescence microscopy. MDDC at 16 h post-infection not infected
(Mock) or infected with MVA-B (at 10 PFU/MDDC) were fixed-permeabilized and viral proteins were stained indirectly with FITC (green) and nucleus
was visualized using Hoechst (blue). These data are representative of two individual experiments. (B) Density plots showing the percentage of Gag
and CD86 double positive MDDC from 0.003 to 3.3 doses (PFU/DC). (C) Linear regression of percentage of double positive CD86 Gag cells versus viral
dose (PFU/MDDC). A representative result of 3 independent experiments is shown. (D) Intracellular Gag expression in MDDC observed by
fluorescence microscopy. MDDC were infected with MVA-B and MVA (at 10 PFU/MDDC) and at 16 h post-infection were stained with PE-CD86 (red)
and fixed-permeabilized and stained with FITC-anti-HIV-Gag (green) antibody and nucleus was stained with Hoechst (blue). These data are
representative of two individual experiments.
doi:10.1371/journal.pone.0019644.g001
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It should be noted that infection of MDDC with MVA resulted in
a similar pattern of viability decay, although it was significantly
slower than that caused by MVA-B, being the number of viable
MVA-infected MDDC 2-fold higher than that of MVA-B-infected
MDDC at 24 h post-infection (p,0.05) (Figure 2A). This finding
suggests that the inserted HIV-1 genes in the MVA-B vector are
somehow involved in causing a higher cytopathic effect compared
with the parental MVA.
We next assessed the effect of infection with MVA and MVA-B
on the maturation state of MDDC. In a dose-response analysis of
CD86 expression and MVA-B dose, at 16 h post-infection, in the
absence of maturation cocktail, 0.3 PFU/MDDC was found to be
the optimal dose at which CD86 expression assessed as MFI was
maximal (Figure 2B). This upregulation of CD86 expression
observed at 16 h post-infection at 0.3 PFU/MDDC dose was also
coupled with the increase, compared with mock-infected MDDC,
of the maturation markers CD80 (from 5.0% to 20.0%), CD83
(from 6.0% to 13.3%), and HLA-DR (from 129.8 MFI to 167.0
MFI) (data not shown). Similar results were obtained for MDDC
infected with MVA (data not shown). These data demonstrate that
infection of MDDC with both MVA and MVA-B is able to induce
by itself a moderate degree of the MDDC maturation, in the
absence of any exogenous maturation agents.
Given that, as indicated above, viral doses of MVA-B higher
than 1 PFU/MDDC caused a high cell death rate of MDDC at
48 h post-infection, while 0.33 PFU/MDDC at 16 h post-
infection appeared as the optimal dose for the upregulation of
CD86 and other maturation markers of MDDC, we next
compared the highest viral dose, 10 PFU/MDDC, and the
optimal dose, 0.33 PFU/MDDC for the effects on maturation and
cell viability. These parameters were assessed at 48 h post-
infection in the presence of complete maturation cocktail.
Although MVA-B infection by itself induces a moderate degree
of MDDC maturation, we opted to add the cytokine maturation
cocktail after MVA-B infection to obtain the highest degree of
maturation, which is a requisite to achieve the highest HIV
antigen presentation to T cells [42]. As shown in Figure 2C, on
MDDC infected with MVA-B at 0.3 PFU/MDDC dose, the
Figure 2. Evaluation of MDDC maturation and viability. (A) Viability assay after MVA and MVA-B infection. Viability was expressed as the
percentage of live cells in front of the total basal population. This experiment was performed in triplicates. (*) p,0.05 (B) At 16 h post-infection, in the
absence of maturation cocktail, CD86 expression was measured as MDDC maturation surface marker by FACS. CD86 (measured MFI) is represented in
a dose-response graphic versus PFU/MDDC at a dose range of 0.003–3.3 PFU/MDDC. This is a representative result of 2 independent experiments. (C)
Expression of maturation markers and viability after MVA-B infection at 0.3 and 10 PFU/MDDC. The maturation cocktail was added during 48 h.
Maturation markers and viability were measured at 48 h post-infection. HLA-DR, HLA-ABC, CD86, CD80, CD83, CD25 expression was measured as DC
maturation surface markers by FACS. Viability was measured by dual Annexin V and 7AAD staining. Live cells were negative for both markers, dead
cells were positive for 7AAD and apoptotic cells were positive for Annexin V and negative for 7AAD. Results are represented as the relative
percentage calculated with respect to the value obtained with uninfected MDDC: (value of infected MDDC/value of uninfected MDDC)6100. The
value was MFI from HLA-DR, HLA-ABC and CD86 or percentage of CD80, CD83, CD25 and viability. (*) p,0.05, (**) p,0.01, (***) p,0.005. Error bars
represent the standard error (SEM) from the mean of the replicates (n = 3). (D) Correlation between relative percentage of viable cells and relative
percentage of CD86.
doi:10.1371/journal.pone.0019644.g002
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expression of all maturation markers was between 2- and 15-fold
higher than MDDC infected with 10 PFU/MDDC dose, with
statistically significant differences being observed for all measured
markers (CD80, CD83, CD25 and CD86, and HLA-ABC and
HLA-DR), expressed as a relative percentage with respect to the
maximal value obtained with cocktail-matured uninfected
MDDC. MDDC viability, measured by dual staining with
Annexin V and 7AAD, was also significantly higher (more than
5-folds) at 0.3 PFU/MDDC than at 10 PFU/MDDC (0.3:
76.5760.5295, 10: 15.0262.607, p,0.0001). Moreover, as shown
in Figure 2D, a positive linear correlation was observed between
MDDC viability and CD86 expression after MVA-B infection and
cocktail-induced maturation (r2 = 0.7377). The same experiments
performed in parallel with the parental MVA showed similar
results as those found for MVA-B (data not shown), indicating that
the maturation effect at 48 h post-infection is dependent on the
MVA vector itself. On the other hand, taken together, the above
results suggest that those MDDC that become infected are going
to die in a 48 h period, while bystander uninfected and viable cells
are those able to undergo the maturation.
Infection of MDDC with MVA-B induced the production
of cytokines, chemokines and IFN-a by MDDC
To further characterize the effects of the infection of MVA and
MVA-B in the biology of MDDC, the levels of secreted cytokines
and chemokines in the culture supernatants of MDDC following
infection with MVA and MVA-B were assessed using the Luminex
technology. Cytokine levels secreted by MDDC following infection
with MVA and MVA-B were assessed under three conditions: at
the high dose of 3.3 PFU/MDDC, after 16 h of infection
(Figure 3A), at the low dose of 0.33 PFU/MDDC at 48 h post-
infection (Figure 3B) and at 0.33 PFU/MDDC after 48 h of
infection but in the presence of maturation cocktail (Figure 3C).
MVA and MVA-B induced the secretion of pro-inflammatory
cytokines (IL-6 and TNF-a) and chemokines (IL-8/CXCL8,
MIP-1a/CCL3, MIP-1b/CCL4, RANTES/CCL5 and IP-10/
CXCL10) by the infected MDDC under all the three conditions
(Figure 3A, B and C). Interestingly, IL1-ra was also up regulated
with MVA-infected MDDC at 16 h post-infection but lower levels
were found, compared with mock, at longer periods of time
(Figure 3C). MVA and MVA-B also induced secretion of IL-12,
but when full maturation was induced, uninfected MDDC also
secreted higher amounts of IL-12 (Figure 3A, B and C). After 48 h
of infection (Figure 3B and C), MVA-B induced higher production
of IL-7, IL-15, MCP-1/CCL2 and MIG/CXCL9 than uninfected
MDDC, indicating that some mediators are secreted at later times
post-infection and/or at low doses possibly because is necessary
some degree of maturation to up regulate such mediators. Similar
results were obtained with MVA (Figure 3C, data not shown in
Figure 3B). In particular, the levels of IL-7 and IL-15 obtained
after MVA and MVA-B infection were approximately 100 fold
higher than after mock-infection without maturation cocktail.
Statistically significant higher levels for most of the mediators
analyzed were observed in MVA versus MVA-B infection
(Figure 3A and C). These results suggest that the inserted HIV
genes from MVA-B are somehow involved in inducing lower
secretion of cytokines comparing with MVA, perhaps as a result of
the higher induction of apoptosis of MVA-B (Figure 2A). These
results also suggest that a positive correlation between viability and
cytokine secretion exists. In Figure 3A, further evidences of this
correlation are provided: at 16 h post-infection, differences
between MVA and MVA-B are more pronounced (the levels of
9 out of 11 cytokines were significantly higher with MVA-infected
MDDC) when the viability differences between MVA and MVA-B
were higher (Figure 2A). On the contrary, at 48 h post-infection,
when the percentage of viable cells was more similar (Figure 2A)
differences between MVA and MVA-B were lower (Figure 3C, the
levels of 6 out of 14 were higher with MVA-infected MDDC).
Finally, MVA and MVA-B up regulated IFN-a, as shown in
Figure 3C.
MVA-B-infected MDDC induced HIV-1-specific CD8+ T cell
proliferation and secretion of CD8-polyfunctional-related
cytokines in autologous T lymphocytes
We next investigated the capacity of autologous MDDC
infected with 1 PFU/MDDC of either MVA-B or MVA to
induce HIV-1-specific CD4+ and CD8+ T cell proliferative
responses in fresh autologous lymphocytes of asymptomatic
HIV-infected patients (n = 5). As shown in Figures 4A and 4B,
MDDC infected with MVA-B induced a significant CD8+ T cell
proliferative response (with a mean percentage of proliferation of
10.662.0%) (Figure 4B). Nearly null proliferation of CD4+ T cells
occurred in response to MDDC infected with either MVA or
MVA-B (Figure 4B). Conversely, CD4+ T cell proliferation
occurred in response to MDDC pulsed with soluble HIV-1 p24
antigen; while this stimulus induced a low level of CD8+ T cell
proliferation (Figure 4B).
The proliferative CD8+ T cell response to MVA-B-infected
MDDC was associated with a high secretion of CD8+-polyfunc-
tional-related cytokines as IFN-c, IL-2, TNF-a, MIP-1b and IL-6
(Figure 4C), and also MIP-1a and RANTES (data not shown).
Negligible levels of IFN-c and IL-2 were secreted in response to
MVA-infected MDDC, while MVA-B-infected MDDC induced a
high secretion of both cytokines (IFN-c: 10.1961.574 ng/ml; IL-
2: 22.4864.10 pg/ml). Secretion of TNF-a, MIP1-b and IL-6 in
response to MDDC infected with MVA-B was significantly higher
than that found in response to MDDC infected with MVA (MVA:
6.16861.187 pg/ml, 2.71860.774 ng/ml and 130.0643.25 pg/
ml, respectively; MVA-B: 18.4662.804 pg/ml, 22.0564.704 ng/
ml and 569.36128.0 pg/ml, respectively) (Figure 4C). Similarly,
MIP-1a and RANTES levels were significantly higher with MVA-
B-infected MDDC (data not shown). In the MDDC alone
supernatant only low amounts of TNF-a, IL-6, MIP-1a and
MIP-1b were found after MVA and MVA-B infection (data not
shown). These values are similar to cytokine levels obtained in the
co-cultures after infection with the MVA vector alone (Figure 4C).
On the other hand, in the lymphocytes alone supernatant, nearly
null levels of cytokines were detected. Moreover, due to the fact
that proliferating CD8+ T cells secrete such cytokines and, as
expected, we have found that CD8+ T cells proliferation in the co-
culture of MVA-B-infected MDDC positively correlated with
these cytokine secretion (Figure 5) and, since CD8+ T cells are the
main proliferating population (95.65% of total proliferation,
Figure 4B), we can assume that the measured cytokines produced
in the supernatants of MVA-B infected MDDC co-cultured with
lymphocytes mainly correspond to the proliferating CD8+ T cells.
Only a residual amount would correspond to CD4+ T cells (4.35%
of the total proliferation, Figure 4B) and only a low secretion of
TNF-a, IL-6, MIP-1a, MIP1-b is induced by the infected MDDC
alone.
The HIV-1-specific T cell proliferative response and cytokine
secretion (IFN-c, IL-2 and TNF-a) were further assessed in a dose-
response study at a MOI range from 0.003 to 3.3 PFU/MDDC.
As shown in Figure 5, the CD8+ T cell proliferative response
showed a MOI-dependent increase to reach a maximum at a
concentration of 0.3 PFU/MDDC, from which the response
decreased up to a plateau starting at around 1 PFU/MDDC.
Thus, 0.3 PFU/MDDC was again found to be the optimal dose
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for CD8+ T lymphocyte proliferation. It should be noted that
HIV-1-specific proliferative response of CD4+ T cells in these
dose-response experiments was also nearly null as it occurred
above with the 1 PFU/MDDC dose (data not shown). The dose-
response curve in terms of secretion of IFN-c, IL-2 and TNF-a
was similar to that of CD8+ T cell proliferation, indicating that a
positive correlation exists between CD8+ T cell proliferation and
secreted cytokines. Indeed, the levels of secreted IFN-c, IL-2 and
TNF-a increased with the dose to reach a peak at around 0.3
PFU/MDDC, from which the response decreased to a constant
Figure 3. Cytokine, chemokine and IFN-a production by MDDC upon infection with MVA and MVA-B. MDDC were infected with MVA or
MVA-B at high doses (3.3 PFU/MDDC) at 16 h post-infection (Figure 3A) and at low doses (0.33 PFU/MDDC) at 48 h post-infection (Figure 3B) and at
48 h post-infection in the presence of maturation cocktail (Figure 3C) and secreted mediators were assessed by Luminex technology. Results are
expressed as mean 6 SD from 4 independent experiments. Error bars represent the SEM from the mean of the replicates (n = 4). (*) p,0.05,
(**) p,0.01, (***) p,0.005.
doi:10.1371/journal.pone.0019644.g003
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level when MOI was$1 PFU/MDDC. Therefore, as observed for
MDDC maturation and CD8+ T cell proliferation, 0.3 PFU/
MDDC was found to be the optimal dose for cytokine secretion
(Figure 5).
The correlation between the maturation degree of MVA-B-
infected MDDC and HIV- specific T cell responses was analyzed.
With this purpose, MDDC were infected at a dose range of 0.003–
3.3 PFU/MDDC and expression of the maturation surface marker
of MDDC, CD86, were measured by FACS. Subsequently,
infected MDDC were co-cultured with autologous T lymphocytes
for 6 days, and the CD8+ T lymphocyte proliferation and secretion
of IFN-c, IL-2, and TNF-a was measured as described above. In
all cases, a direct and significant correlation was observed between
CD86 expression (MFI) and the percentage of CD8+ T
lymphocyte proliferation and levels of secreted IFN-c, IL-2 and
TNF-a secretion, with correlation coefficients (r2) of 0.6955,
0.7525, 0.5980 and 0.6643, respectively (Figure 6).
CD8+ T cells activated by MVA-B-infected MDDC showed
cytotoxic activity against autologous HIV-infected CD4+ T
cells
After co-culture for 6 days with MVA-B-infected MDDC (at a
ratio of 0.3 PFU/MDDC) CD8+ T lymphocytes showed a strong
cytotoxic activity against HIV-infected autologous CD4+ T lym-
phocytes. After a co-culture of 4 hours between stimulated CD8+
T cells and HIV-infected CD4+ T cells, the CD4 count showed a
69.8% of reduction, from a mean of 5.026103 cells to 1.526103
cells when MVA-B was used. By contrast, CD8+ T cells stimulated
with MDDC infected with the parental strain (MVA) showed a
slight cytotoxic activity with a mean of 10.4% of reduction (from
5.026103 to 4.56103), with statistically significant differences
being obtained between MVA and MVA-B (p = 0.0160)
(Figure 7B).
MVA-B-exposed MDDC after induction of fully
maturation were able to migrate toward a chemokine
gradient
It is known that MVA inhibits directional migration of mature
DC toward the lymphoid chemokines CCL19 and CCL21 without
affecting surface expression of the CCR7 chemokine receptor or
impairing undirected cellular locomotion [43]. For this reason, we
assessed the influence of MVA and MVA-B infection (at 0.3 PFU/
MDDC) on the capacity of infected mature MDDC to migrate
toward a gradient of chemokines CCL19 and CCL21. Both
uninfected (mock) and MVA- and MVA-B-infected MDDC were
matured for 48 h with the maturation cytokine cocktail. As shown
Figure 4. HIV-1-specific T-cell proliferation and cytokine secretion induced by autologous MDDC infected with MVA-B. T cell
proliferation in response to autologous MDDC infected with MVA-B at 1 PFU/MDDC in a 6-day co-culture was assessed in triplicates using the CFSE
proliferation assay. In (A), a representative (out of 5 independent experiments) flow cytometry plots showing CFSE dilution in gated CD3+ CD8+ T
lymphocytes after in vitro stimulation with MVA- and MVA-B-infected MDDC. In (B), the % of CFSElow cells in the CD3+ CD8+ and CD3+ CD82 (CD4+)
gates responding to MVA-, MVA-B-infected and soluble HIV1p24-pulsed MDDC are shown. Error bars represent the SEM from the mean of 5 patients
(n = 5). (***) p = 0.005, (**) p,0.01. (C) Cytokine secretion after co-culture of MVA or MVA-B-infected MDDC and CD8+ T lymphocytes. Concentrations
of IFN-c, IL-2, TNF-a, MIP-1b and IL-6 are represented. (***) p,0.005, (**) p,0.01, (*) p,0.05. Error bars represent the SEM from the mean of 5
patients.
doi:10.1371/journal.pone.0019644.g004
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in Figure 8A, where the results of six experiments with cells from
different patients are depicted, compared with mock-infected
MDDC (25.21%), both MVA and MVA-B infections reduced the
migration of MDDC at 48 h post-infection (16.82% for MVA and
21.53% for MVA-B). However, MVA-B infection inhibited
MDDC migration to a lesser extent than MVA did, although
this difference did not reach statistical significance (21.53%,
p = 0.029 vs negative control and p = 0.261 vs MVA). Similar
results were also obtained in the same migration assay using
chemokine CCL21 (data not shown). On the other hand,
migration evaluation performed at 48 h and 72 h post-infection
and maturation with uninfected (Mock) and MVA- and MVA-B-
infected MDDC showed a clear increase, higher than 2-folds, in
the number of migrated cells at 72 h compared with 48 h (in
MVA-B-exposed MDDC migration increased from 10.05% at
48 h to 30.38% at 72 h, p = 0.0005) (Figure 8B). These results
indicated that longer periods of maturation would induce a higher
degree of migration.
We also analyzed whether MDDC that had been exposed to
both MVA and MVA-B and had migrated to CCL19 were
capable of inducing lymphoproliferative responses. For this
purpose, migrated cells were collected and immediately co-
cultured for 6–7 days with fresh autologous T lymphocytes. As
shown in Figure 8C, migrated MDDC infected with MVA-B
induced specific CD8+ T cell proliferation, with a proliferation rate
10-fold higher than that obtained with MDDC pulsed with MVA
(18.0% vs 1.7%, p,0.0001, Student’s t test) (Figures 8C and 8D).
Upon MVA-B infection, MDDC underwent apoptosis and
were phagocytosed by uninfected bystander MDDC that
cross-presented HIV-1 antigens to CD8+ T lymphocytes
The cytopathic effects of MVA-B infection (see Figure 2A and
2C) and the capacity of viable, mature and migrated MDDC to
induce the proliferation of HIV-specific CD8+ T lymphocytes
documented above suggest that these cells correspond to those
MDDC that captured apoptotic MVA-infected MDDC and then
cross-presented HIV antigens to HIV-specific CD8+ T cells. To
test this hypothesis we first evaluated the capacity of uninfected
MDDC to engulf the apoptotic bodies resulting from MVA-B
infection on MDDC. To this end, CFSE-labeled immature
MDDC were infected with MVA and MVA-B at a MOI of 10
PFU/MDDC for one hour and then mixed with uninfected
immature MDDC at a ratio of 1:2 (infected:uninfected) and
incubated with the maturation cocktail for 48 h. Afterward,
staining of cell-surface CD80 was performed and then phagocy-
tosis of MVA-B-infected MDDC by uninfected MDDC was
assessed by flow cytometry considering the phenotypes CFSE+
CD802 (dead MVA-B-infected MDDC), CFSE2 CD80+ (unin-
fected matured MDDC), CFSE+ CD80+ (CD80+ uninfected
matured MDDC that ingested apoptotic CFSE+ MDDC during
the incubation period). As depicted in Figure 9A, the percentage of
MDDC that ingested apoptotic bodies was 40.3%. These results
were also confirmed by fluorescence microscopy, where phagocy-
tosis was indicated by the localization of apoptotic cells or
apoptotic bodies (CFSE, green colour) within CD80-positive
MDDC (PE, red colour) (Figure 9B).
As indicated above, at a concentration of 0.3 PFU/MDDC, a
maximum response was obtained not only in terms of MDDC
maturation and viability, but also in terms of CD8+ T cell
lymphoproliferative and cytokine secretion responses (Figure 2A,
Figures 5A and 5B). Based on all these results, we hypothesized
that after MVA-B infection at an optimal dose of 0.3 PFU/
MDDC, approximately one third of the MDDC culture is
infected, resulting in their apoptosis and converted into apoptotic
bodies, while approximately the other two thirds of the initial
mature MDDC would remain uninfected, being able to engulf the
cell debris containing MVA-B-mediated HIV-1 expressed antigens
and to maturate properly and, thus, cross-present the HIV
Figure 5. Dose-response analysis of HIV-1-specific T-cell
proliferation and cytokine secretion in response to autologous
MVA-B-infected MDDC. T cell proliferation and cytokine secretion
(IFN-c, IL-2 and TNF-a secretion) in response to autologous MDDC
infected with different doses of MVA and MVA-B (from 0.003 to 3.3 PFU/
MDDC) are depicted. A representative result of 2 independent
experiments is shown. Error bars represent the SEM from the mean of
the replicates (n = 2). Co-culture procedure and methods followed are
described in Figure 4.
doi:10.1371/journal.pone.0019644.g005
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antigens to CD8+ T lymphocytes. Results obtained clearly support
this hypothesis. Indeed, as can be seen in Figure 9C, similar HIV-
1-specific CD8+ T cell lymphoproliferative responses were
obtained in the model of optimal infection (0.3 PFU/MDDC)
and in a model where a ratio of 1:2 (apoptotic bodies: uninfected
MDDC) was used, with no significant differences between both
experiments (optimal dose: 6.97% of CD8+ proliferation; apoptot-
ic bodies: 6.81% of CD8+ proliferation, p = 0.8383). Of note,
additional experiments in which the apoptotic bodies were heat-
inactivated at 55uC for one hour resulted in a similar proportion
(5.00%) of HIV-1-specific CD8+ T cell proliferation. These results
indicate that the HIV-1-specific CD8+ T cell proliferation induced
by MVA-B-infected MDDC is mainly due to cross-presentation of
HIV-1 antigens.
Discussion
After the failure of the adenovirus-based anti-HIV vaccines at
phase III clinical studies 2008 [10–12] and with the publication in
2009 of the first promising results of a prophylactic anti-HIV
vaccine based on poxviruses vectors [13], basic and clinical
research with poxviruses such as MVA has notably increased.
Since MVA-B is currently being evaluated in phase I clinical trials
and due to the essential role of MDDC in the development of an
efficient immune response, the present study investigated, in an ex
vivo model, the impact of MVA-B infection on the biology of
MDDC from asymptomatic HIV-1-infected patients, and the
capacity of MVA-B-infected MDDC of these patients to induce
HIV-1-specific T cell responses in autologous T lymphocytes. In
that setting, another more specific goal was to assess whether
MVA-B could be used as an immunogen in a DC-based effective
therapeutic HIV-1 vaccine. The in vitro model using autologous
fresh MDDC from asymptomatic HIV-infected patients is
considered a more realistic scenario to support the efficacy of
these type of therapeutic vaccines (where HIV could have
influenced on MDDC biology), in comparison with other models
using MDDC from healthy volunteers [20].
Data obtained in the present study demonstrate that MVA-B-
infected MDDC from HIV patients express Gag intracellular
protein, consistently with our previous works with MDDC from
healthy subjects [44], and with other recent studies using other
MVA vectors carrying HIV-1 genes [20]. Our data revealed that
the expression of intracellular Gag was dose-dependent and we
also found that MVA and MVA-B infection produced a rapid
cytopathic effect on the infected cells, being this phenomenon
associated with direct infection of the cells. These results are
consistent with previous reports using MDDC from healthy
individuals infected with MVA vectors expressing HIV antigens
[17,18,20]. In our study, we extended infection up to 72 hours,
when we observed a nearly null percentage of viable cells infected
with both MVA and MVA-B. Of note, MVA-B induced a more
rapid apoptosis than MVA, in agreement with other reports using
another HIV-1-MVA construct [17]. In this context, HIV proteins
expressed by MVA-B could be involved in this quicker induction
of apoptosis. We also found that MVA and MVA-B infection
induces MDDC maturation in a dose-dependent manner, being
maximal at 0.3 PFU/MDDC, may be due to the fact that infected
MDDC secreted TNF-a, IL-6 and type I IFN, which are known to
induce DC maturation [42,45–47]. Interestingly, at this dose,
uninfected bystander DC in contact with MVA or MVA-B-
infected cells underwent phenotypic maturation without apoptosis
and without any maturation factor added, in accordance with
studies in MDDC from healthy volunteers and in murine DC
[20,48]. In agreement with these previous works, at higher MOIs,
viability was drastically reduced and we found that it was coupled
with a marked decrease of maturation markers.
To advance in the knowledge of cytokine secretion from
previous studies [20], where production of IFN-a was assessed, we
Figure 6. Correlation between CD86 expression on MVA-B-infected MDDC and HIV-1-specific CD8+ T-cell proliferation and cytokine
secretion. MDDC were infected with MVA-B at serial three-fold dilutions (from 0.003 to 3.3 PFU/MDDC) and expression of the maturation surface
marker of MDDC, CD86, measured by flow cytometry at 16 h post-infection in the absence of maturation cocktail was assessed. Subsequently, MVA-
B-infected MDDC matured with cytokine cocktail were co-cultured for 6 days with autologous lymphocytes and HIV-1-specific CD8+ T proliferation
and cytokine secretion were measured. A representative result of 2 independent experiments is shown.
doi:10.1371/journal.pone.0019644.g006
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have analyzed the production of an array of 25 cytokines by
MDDC of asymptomatic HIV-1-infected patients after infection
with MVA and MVA-B, and we found that the secretion of 13 of
such mediators (IFN-a, IL1-ra, IL-12p40/p70, IL-15, IL-6, IL-7,
IL-8, IP-10/CXCL10, MCP-1/CCL2, MIG/CXCL9, MIP-1a/
CCL3, MIP-1b/CCL4, RANTES/CCL5 and TNF-a) was
upregulated. These results are in accordance with our previous
studies demonstrating that infection with MVA or MVA-B of
immature MDDC from healthy individuals upregulated the
expression of most genes encoding the above mentioned
immunomodulators (IFNa, IFNb, TNFa, IL-6, IL12b, CCL3,
CCL4, CCL5 and CXCL10) [18,44]. Production of most of these
cytokines was recently also found in human macrophages infected
with MVA [49]. In agreement with our results, recent studies
described secretion of IFN-a [20,43] and we have also previously
shown secretion of IFN-b [44] in human MVA-infected MDDC.
IFN-a is involved of upregulation of inflammatory chemokine
receptors such as CCR1, and CXCR1 by uninfected bystander
DC [43]. On the other hand, we also showed that MVA or MVA-
B-infected cells secrete high amounts of MCP-1, CCR5 and
CCR1 ligands such as MIP-1a, MIP-1b and RANTES that would
promote the attraction of uninfected MDDC to the inflammation
site [43,50], where they can engulf the apoptotic infected MDDC.
Interestingly, these CCR5-chemokines inhibit HIV-1 infection of
CCR5-tropic (R5) HIV-1 isolates [51], suggesting that MVA-
infected DC would inhibit HIV infection. In this context, IFN-a is
also known to exert important antiviral effects and exogenously
added IFN-a has been shown to inhibit HIV replication [20,52]
and to limit HIV cell-to-cell spread [20,53]. Consistent with the
IFN-a secretion observed after MVA and MVA-B infection of
MDDC, the present study also described secretion of MIG/
CXCL9, which, together with IP-10/CXCL10, is known to be
markedly upregulated in the presence of IFN-a [54]. MIG and IP-
10 stimulate the directional migration of activated T cells, thus
contributing to induce HIV-specific CTL responses [55]. Impor-
tantly, we demonstrate for the first time that MDDC infected with
MVA and MVA-B, secrete IL-7 and IL-15 at levels more than 30-
fold higher than the negative control after 48 h post-infection
Figure 7. Cytotoxic activity of CD8+ T lymphocytes activated by MVA-B-infected MDDC. Effector cells were autologous monocyte-
depleted PBMC co-cultured for 6 days with MDDC mock-treated or infected with MVA or MVA-B. After this co-culture period, CFSE staining of effector
cells was performed and then were cultured for 4 h with target cells at a 10:1 ratio. Target cells were autologous CD8-depleted T cells infected with a
primary HIV-1 isolate and their corresponded to the phenotype CFSE-negative, CD3-positive CD8-negative. In (A) the flow cytometry analysis is
shown. In (B), the mean (6SEM) count of target CD4+ T cells is a representative result of three independent experiments (performed in triplicates) is
depicted. (*) p,0.05.
doi:10.1371/journal.pone.0019644.g007
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without maturation cocktail. IL-7 and IL-15 were detected
previously after MVA infection of HeLa cells [27]. IL-7 is a T
cell homeostatic cytokine [56] that regulates the ability of T cells to
interact with DC, thereby influencing both T cell priming and
homeostasis [57]. In a recent study, IL-7 secretion has been
upregulated in CD40L-mature MDDC, having a relevant role as a
‘‘costimulator’’ cytokine during DC/antigen activation leading to
an increased expansion of antigen-specific CD8+ T cells [58]. Of
note, our work has reported IL-7 levels about 10-fold higher than
those obtained in this previous study [58], which is consistent with
the high HIV-specific CD8+ T cell proliferation observed, which
would be enriched in long memory CD8+ T cells due to the fact
that IL-7 and IL-15 are also upregulated [59,60]. The present
study also showed secretion of IL-8 chemokine. Interestingly, in a
recent study of SHIV infection, higher plasma levels of IL-8 were
associated with lower susceptibility to infection [61], presumably
due to the neutrophil attractant activity of IL-8 [61]. We speculate
that this activity would stimulate defensin-1 and defensin-2 release
[62], which in immature MDDC have been associated with slower
disease progression in HIV patients as we have recently
demonstrated [63]. Regarding IL-12, secreted levels were higher
upon MVA and MVA-B infection than in uninfected MDDC.
Previous results suggest that MVA specially induce IL-12p40
(IL12b gene) [18,49], thus allowing MDDC to maturate and
subsequently to develop an enhanced CD8+ T cell response
[64,65], which is recommended for a vaccine against HIV-1
infection [66,67].
Since MDDC pulsed with MVA-B is currently being developed
to be tested in clinical trials, one of the main aims of this study was
also to find the optimal MOI at which MVA-B-infected MDDC
activate strong HIV-specific immune responses. The dose of 0.3
PFU/MDDC was found to be the optimal one for MDDC
Figure 8. Chemotaxis assay. Chemokine-induced migration of infected mature MDDC was tested 48 h and 72 h after infection in a chemotaxis
assay (n = 6). Entire populations that migrated toward CCL9 and CCL21 were collected after incubation and counted during one minute by flow
cytometry. The number of migrated DC is depicted in percent of the initial input. Subsequently, infected (MVA and MVA-B) and uninfected MDDC
that migrated in the chemotaxis assay were collected and co-cultured with CFSE labeled autologous lymphocytes at a 1:40 ratio (56103 MDDC:
26105 lymphocytes/well). After a period of 6 days, proliferation was tested by flow cytometry. (A) Percentage of CCL19 specific migration of MVA-B-
infected MDDC 48 hours after infection. Error bars represent the mean (6SEM) from 6 independent experiments with 6 different HIV-1 patients (n = 6)
performed in triplicates. (B) Percentage of CCL19 specific migration of MVA and MVA-B-infected and uninfected MDDC (Mock) 48 and 72 h post-
infection and maturation. Error bars represent the mean (6SEM) from 3 independent experiments with 3 different HIV-1 patients (n = 3) performed in
triplicates. (C) Representative flow cytometric plots showing CFSE dilution in gated CD3+ CD8+ lymphocytes after co-culture with MVA and MVA-B
infected MDDC that were able to migrate in the chemotaxis assay. One representative result of 2 independent experiments is shown. Error bars
represent the mean (6SEM) (n = 3). (D) Percentage of CFSElow cells in the CD3+ CD8+ gate, observed in one sample. Error bars represent the SEM from
the mean triplicates (***) p = 0.005.
doi:10.1371/journal.pone.0019644.g008
HIV-1-Specific CD8+ Responses to MVA-B-Exposed DC
PLoS ONE | www.plosone.org 13 May 2011 | Volume 6 | Issue 5 | e19644
viability, maturation and high levels of Gag-antigen expression,
and, accordingly, it was also found to be the optimal dose for HIV-
1-specific CD8+ T cell responses. In this context, we have shown
that MVA-B infection of MDDC stimulates a strong HIV-immune
response, mainly induced by CD8+ T cell proliferation and
coupled with a high secretion of CD8+-polyfunctional-related
cytokines. Such CD8-immunoresponses are considered as an
important immune correlate of protection against HIV-1 [68–73],
more complete than the assessment of IFN-c by ELISPOT
performed in previous studies [20]. In addition, MIP-1a, MIP-1b
and RANTES secreted by CD8+ T cells would inhibit HIV-1
infection [74,75]. What is more, for the first time, the present study
has evaluated cytotoxic responses induced by MVA-B using HIV-
infected CD4+ lymphocytes as target cells. Results obtained have
clearly shown that MVA-B infection induces a strong cytotoxic
activity by stimulated CD8+ T lymphocytes (69.8% reduction of
target cells), thus demonstrating that the combination of MDDC
and MVA-B is able to destroy the main target cells where HIV
replicates, which could be used as a direct marker of the efficacy of
vaccine candidates [76].
Another important advance of this study in comparison with
previous works [20] is the demonstration that after MVA and
MVA-B exposure, MDDC are able to migrate toward a gradient
to chemokines secreted by lymph nodes. It had been postulated
that different strains of vaccinia virus could interfere in DC
functions, in particular, inhibiting migration to secondary
lymphoid organs [43,77]. MVA inhibited directional migration
of infected and bystander immature DC subsequently matured
with LPS for 24 h toward a gradient of CCL19 chemokine [43].
Based on these observations, we also assessed the migration
capacity of MDDC infected with MVA and MVA-B and
subsequently fully maturated to migrate toward a gradient of
chemokines CCL19 and CCL21 (found in lymph nodes and whose
receptor -CCR7- is expressed in mature DC) 48 h and 72 h after
infection. We observed that migration of MDDC infected with
MVA was significantly reduced in comparison with uninfected
Figure 9. Antigen presentation study. (A) Phagocytosis assay. Immature MDDC were labeled with CFSE and infected with MVA at a MOI of 10
PFU/MDDC for 1 hour. They were then extensively washed and mixed with uninfected immature MDDC (ratio 1:2) and maturation was induced for
48 h. Phagocytosis of apoptotic bodies resulting from MVA-infected MDDC by uninfected MDDC were detected by flow cytometry. Density plots
showing infected MDDC, detected as CFSE+ CD802 (left box), uninfected MDDC, detected as CFSE2 CD80+ (middle box) and CD80+ MDDC that
ingested apoptotic CFSE-labeled MDDC during the incubation period, detected as CFSE+ CD80+ (right box). These data are representative of two
individual experiments. (B) Phagocytosis assessed by fluorescence microscopy. Phagocytosis of apoptotic bodies resulting from MVA-infected MDDC
by uninfected MDDC were visualized by fluorescence microscopy. MVA-B infected MDDC were CFSE+ CD802 (green colour), uninfected matured
MDDC were stained CFSE2 CD80+ antibody (red colour), nucleus was visualized with Hoechst staining (blue colour) and phagocytosis was observed
as CFSE stained vacuoles (green) inside the MDDC CD80 positive cells (red). As negative controls of phagocytosis, uninfected MDDC and infected
MDDC cultured separately were used. These data are representative of 2 independent experiments. (C) Cross-presentation induced proliferation of
CD8+ T cells. Representative dot plots showing the proliferation rate of CD8+ T cells after co-culture between infected MDDC with autologous
lymphocytes. The white plots correspond to a MVA-B infection model at 0.3 PFU/MDDC. The black plots correspond to infection of immature MDDC
(two thirds of the initial culture; cultured during 72 hours) with apoptotic bodies (obtained after infection of MDDC –one third of the initial culture-
with MVA-B at a dose of 10 PFU/MDDC and during a period of 72 hours). The grey plots correspond to infection between immature MDDC and
apoptotic bodies obtained as described above and subsequently heat-inactivated at 55uC for one hour. Subsequently, infected MDDC were collected
and co-cultured with CFSE labeled autologous lymphocytes in triplicates. Six days after, proliferation was tested by flow cytometry. These data are
representative of 3 individual experiments.
doi:10.1371/journal.pone.0019644.g009
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cells but, in contrast, MVA-B impaired MDDC migration to a
lesser degree. Of note, we demonstrated that the fraction of
migrated cells maintained their capacity to stimulate HIV-specific-
CD8+ T lymphoproliferative responses and that the migration
capacity after MVA-B infection increased with time, being
maximal at 72 h post-infection, when MDDC had fully maturated
and, consequently, had increased their capacity to migrate.
Previous studies reported a higher impairment of migration not
only in MVA-infected MDDC but also in bystander MDDC,
maybe due to the lower times of maturation period (migration was
evaluated 24 h post-infection) [43], thus probably not giving
enough time to MDDC to fully maturate and to undergo
upregulation of CCR7. In the observed higher migration capacity
of MVA-B-infected MDDC, we think that the expression of HIV
proteins could have a role in accelerating apoptosis and inducing a
lower proinflammatory chemokine expression (as demonstrated in
this study), which would allow a slightly higher degree of
maturation by the added maturation cocktail. In any case, results
of this study have clearly demonstrated that upon MVA-B
infection, bystander and viable MDDC are able to capture HIV
antigens and, after full maturation, are able to migrate toward a
gradient of CCL19 and CCL21, thus they would be competent to
reach secondary lymphoid organs. What is more, migrated
MDDC mainly interact with CD8+ T lymphocytes and stimulate
HIV-specific immune responses. Since the migration capacity
toward lymph nodes is an essential function of antigen presenting-
cells such as MDDC, we think these results are a surrogate marker
of the efficacy of these MVA-B based vaccines that are being tested
in clinical trials.
Our results also demonstrated that the induction of CD8+ T cell
mediated immunity after interaction with MVA-B-infected
MDDC mainly depended on cross-presentation, being these
results consistent with previous observations [20,48,78,79]. In
comparison with previous works in which cross-presentation was
reported after contact of MVA-HIV-infected epithelial cells or
myotubes with DC [20], the novelty of our study is that we
described for the fist time the cross-presentation phenomenon after
interaction between two types of MDDC: the apoptotic MVA and
MVA-B infected MDDC and the bystander MMDC (of particular
relevance for a MDDC based vaccine). The apoptosis observed
after MVA and MVA-B infection has been proposed as a reason
for its greater immunogenicity, presumably through an enhanced
release of nucleotides, HIV-antigen degradation and enhanced
cross-presentation to CD8+ T cells [80–82]. Another explanation
for the strong induction of CD8+ T cell responses with very low
activation of CD4+ T cells would be the induced secretion of
cytokines by MVA-infected MDDC as Type I IFN [83], IL-7 [58]
and IL-12 [64,65]. IFN-a-stimulated DC can induce cross-
presentation to CD8+ T cells without the help of CD4+ T cells
in murine models [83] and immunized hu-PBL-SCID mice with
inactivated HIV-1-pulsed IFN-a-stimulated MDDC induced
HIV-1-specific CD8 responses and protection from a virus
challenge [34,84]. On the other hand, it should be noted that
the polypeptide Gag-Pol-Nef expressed by MVA-B-infected
MDDC would have the recommended properties to induce strong
HIV-specific immune responses in comparison with shorter and
more unstable antigens, since long and stable mature protein
antigens have been shown to be the best substrates for cross-
presentation [78]. In view of that, in recent studies, it has been
shown that infection of mice with MVA-B and the poxvirus vector
NYVAC-B-C7L expressing the same HIV genes than MVA-B also
induced mainly CD8+ T cell responses in vivo, thus highlighting the
potential of this type of vectors to control latent and reactivating
viruses [19,85,86].
In conclusion, we have shown that, upon MVA-B infection,
MDDC can induce apoptosis, production of cytokines, antigen
capture and maturation. MVA-B-exposed MDDC would migrate
to lymph nodes and induce a highly functional HIV-specific CD8+
T cells response capable to effectively eliminate HIV-infected cells.
Therefore, these results support the clinical research of prophy-
lactic and therapeutic MDDC and MVA vaccines and, in
particular, of MVA-B based vaccines against HIV infection.
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